Johnson & Johnson Stock Forecast 2025–2030 | Future Outlook
The stock has risen approximately 31% year to date, reaching new all-time highs amid a broader healthcare sector rally (Reuters, 1 October 2025).
The healthcare giant’s recent momentum reflects renewed investor confidence following relief across the pharmaceutical sector over a potential tariff reprieve, after Trump administration agreements with companies such as Pfizer (Reuters, 13 October 2025). This comes ahead of the company’s third-quarter earnings on 14 October, with analysts projecting earnings growth and solid performance across its MedTech and oncology divisions, despite ongoing biosimilar competition affecting its blockbuster drug Stelara (Yahoo Finance, 26 September 2025).
